Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability
BOSTON - The U.S. Attorney's Office announced today that pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve allegations that they violated the False Claims Act by knowingly misclassifying EpiPen, a branded epinephrine auto-injector drug, as a generic drug to avoid paying rebates owed to Medicaid. Mylan Inc. and Mylan Specialty L.P. are both wholly owned subsidiaries of Mylan N.V., a Dutch-registered entity headquartered in Canonsburg, Penn.
- Date:August 17, 2017
- Agency:U.S. Attorney
- Criminal and Civil Actions